Hyderabad Telangana, India

Shaikh Faazil Bagwan

This inventor holds 1 USPTO granted patent. Top assignee: Council of Scientific and Industrial Research. Active years: 2015.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Shaikh Faazil Bagwan in Anticancer Research

Introduction

Shaikh Faazil Bagwan is an innovative inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of cancer research through his inventive work. His dedication to developing potential anticancer agents showcases his commitment to advancing medical science.

Latest Patents

Shaikh Faazil Bagwan holds a patent for "2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof." This invention provides a compound of general formula A that is useful as potential antitumor agents against human cancer cell lines. The process for the preparation of this compound is also detailed in the patent, highlighting its significance in the fight against cancer.

Career Highlights

Shaikh Faazil Bagwan is associated with the Council of Scientific and Industrial Research, where he continues to work on innovative solutions in the field of science. His research focuses on developing compounds that can effectively combat cancer, contributing to the broader scientific community's efforts in this critical area.

Collaborations

Some of his notable coworkers include Syed Mohammed Ali Hussaini and Mohammed Ashraf. Their collaborative efforts enhance the research environment and foster innovation in their projects.

Conclusion

Shaikh Faazil Bagwan's work exemplifies the spirit of innovation in the field of cancer research. His patent and ongoing contributions reflect his commitment to finding effective solutions for one of the most pressing health challenges of our time.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…